Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Immune Environment in Glioblastoma (Feb 2023)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editor's notes
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
FOXK2 promotes ovarian cancer stemness by regulating the unfolded protein response pathway
Yaqi Zhang, … , Mazhar Adli, Daniela Matei
Yaqi Zhang, … , Mazhar Adli, Daniela Matei
Published March 29, 2022
Citation Information: J Clin Invest. 2022;132(10):e151591. https://doi.org/10.1172/JCI151591.
View: Text | PDF
Research Article Cell biology Oncology

FOXK2 promotes ovarian cancer stemness by regulating the unfolded protein response pathway

  • Text
  • PDF
Abstract

Understanding the regulatory programs enabling cancer stem cells (CSCs) to self-renew and drive tumorigenicity could identify new treatments. Through comparative chromatin-state and gene expression analyses in ovarian CSCs versus non-CSCs, we identified FOXK2 as a highly expressed stemness-specific transcription factor in ovarian cancer. Its genetic depletion diminished stemness features and reduced tumor initiation capacity. Our mechanistic studies highlight that FOXK2 directly regulated IRE1α (encoded by ERN1) expression, a key sensor for the unfolded protein response (UPR). Chromatin immunoprecipitation and sequencing revealed that FOXK2 bound to an intronic regulatory element of ERN1. Blocking FOXK2 from binding to this enhancer by using a catalytically inactive CRISPR/Cas9 (dCas9) diminished IRE1α transcription. At the molecular level, FOXK2-driven upregulation of IRE1α led to alternative XBP1 splicing and activation of stemness pathways, while genetic or pharmacological blockade of this sensor of the UPR inhibited ovarian CSCs. Collectively, these data establish what we believe is a new function for FOXK2 as a key transcriptional regulator of CSCs and a mediator of the UPR, providing insight into potentially targetable new pathways in CSCs.

Authors

Yaqi Zhang, Yinu Wang, Guangyuan Zhao, Edward J. Tanner, Mazhar Adli, Daniela Matei

×

Figure 7

Effects of IRE1α rescue on stemness characteristics in FOXK2-deficient cells.

Options: View larger image (or click on image) Download as PowerPoint
Effects of IRE1α rescue on stemness characteristics in FOXK2-deficient c...
(A and B) mRNA expression levels of ERN1 measured by qRT-PCR (n = 3) (A), and protein levels (n = 3) by Western blotting of IRE1α, XBP1s, and XBP1u (B) in shCtrl and shFOXK2 OVCAR5 cells transfected with IRE1α-expressing plasmid (shCtrl-IRE1α, shFOXK2-IRE1α) or EV (shCtrl-EV, shFOXK2-EV). (C) RT-PCR–measured XBP1 mRNA splicing (XBP1u, full-length transcript; XBP1s, spliced isoform) in shCtrl and shFOXK2 OVCAR5 cells transfected with IRE1α or EV. (D) Percentage of ALDH+ cells measured by flow cytometry (n = 3) in shCtrl and shFOXK2 OVCAR5 cells transduced with IRE1α or EV. (E) Pictures of spheroids (left) and spheroid formation (n = 4) assessed by cell viability assay (right) in shCtrl and shFOXK2 OVCAR5 cells transfected with EV or IRE1α (original magnification, ×20). (F) qRT-PCR–measured mRNA expression levels (n = 3) of stemness genes (SOX2, OCT4, NANOG) and CSC marker ALDH1A1 in shCtrl and shFOXK2 OVCAR5 cells transfected with IRE1α (shCtrl-IRE1α, shFOXK2-IRE1α) or EV (shCtrl-EV, shFOXK2-EV). (G) Log-fraction plot of xenografts formed by the indicated numbers of shCtrl and shFOXK2 cells transduced with EV or IRE1α (n = 12) generated from ELDA. (H) ALDH+ CSC percentages among cells dissociated from xenografts derived from shCtrl and shFOXK2 cells transduced with EV or IRE1α. *P < 0.05; **P < 0.01; ***P < 0.005; ****P < 0.0001, by unpaired, 2-tailed Student’s t test when comparing 2 groups and 2-way ANOVA with Tukey’s multiple comparisons test when comparing more than 2 groups.

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts